BioCryst (BCRX) Receives Prelim. Comment Letter from FDA for Peramivir
Tweet Send to a Friend
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that it received
a preliminary comment letter from the U.S. Food & Drug Administration ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
a preliminary comment letter from the U.S. Food & Drug Administration ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE